Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study

Farrukh T. Awan, Michael J. Thirman, Dipti Patel-Donnelly, Sarit Assouline, Arati V. Rao, Wei Ye, Brian Hill, Jeff P. Sharman

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Entospletinib (GS-9973), an oral, selective inhibitor of spleen tyrosine kinase (SYK), was evaluated as monotherapy in this multicenter, phase 2 study (NCT01799889) of 49 patients with relapsed or refractory chronic lymphocytic leukemia (CLL), including those with Richter’s transformation (RT), who had received prior therapy with a B-cell receptor (BCR) inhibitor. Patients were treated with entospletinib 400 mg BID as the starting dose. Sixteen patients achieved partial response and 21 had stable disease. The overall response rate was 32.7% (95% confidence interval [CI]: 21.7–45.3%). The median progression-free survival (PFS) was 5.6 (95% CI: 3.7–8.3) months. Twenty-one (of 43) patients (48.8%) experienced nodal response. Adverse events (AEs) occurred in all patients; most commonly fatigue, diarrhea, and anemia. Entospletinib monotherapy has clinical activity for patients with CLL and RT who have relapsed following therapy with BCR inhibitors.

Original languageEnglish (US)
Pages (from-to)1972-1977
Number of pages6
JournalLeukemia and Lymphoma
Volume60
Issue number8
DOIs
StatePublished - Jul 3 2019
Externally publishedYes

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
B-Lymphocytes
Confidence Intervals
Disease-Free Survival
Fatigue
Anemia
Diarrhea
Therapeutics

Keywords

  • B-cell receptor inhibitors
  • Richter’s transformation
  • SYK

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors : results of a phase 2 study. / Awan, Farrukh T.; Thirman, Michael J.; Patel-Donnelly, Dipti; Assouline, Sarit; Rao, Arati V.; Ye, Wei; Hill, Brian; Sharman, Jeff P.

In: Leukemia and Lymphoma, Vol. 60, No. 8, 03.07.2019, p. 1972-1977.

Research output: Contribution to journalArticle

Awan, Farrukh T. ; Thirman, Michael J. ; Patel-Donnelly, Dipti ; Assouline, Sarit ; Rao, Arati V. ; Ye, Wei ; Hill, Brian ; Sharman, Jeff P. / Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors : results of a phase 2 study. In: Leukemia and Lymphoma. 2019 ; Vol. 60, No. 8. pp. 1972-1977.
@article{fe03b7cf1b7846618b064d5ca229d182,
title = "Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study",
abstract = "Entospletinib (GS-9973), an oral, selective inhibitor of spleen tyrosine kinase (SYK), was evaluated as monotherapy in this multicenter, phase 2 study (NCT01799889) of 49 patients with relapsed or refractory chronic lymphocytic leukemia (CLL), including those with Richter’s transformation (RT), who had received prior therapy with a B-cell receptor (BCR) inhibitor. Patients were treated with entospletinib 400 mg BID as the starting dose. Sixteen patients achieved partial response and 21 had stable disease. The overall response rate was 32.7{\%} (95{\%} confidence interval [CI]: 21.7–45.3{\%}). The median progression-free survival (PFS) was 5.6 (95{\%} CI: 3.7–8.3) months. Twenty-one (of 43) patients (48.8{\%}) experienced nodal response. Adverse events (AEs) occurred in all patients; most commonly fatigue, diarrhea, and anemia. Entospletinib monotherapy has clinical activity for patients with CLL and RT who have relapsed following therapy with BCR inhibitors.",
keywords = "B-cell receptor inhibitors, Richter’s transformation, SYK",
author = "Awan, {Farrukh T.} and Thirman, {Michael J.} and Dipti Patel-Donnelly and Sarit Assouline and Rao, {Arati V.} and Wei Ye and Brian Hill and Sharman, {Jeff P.}",
year = "2019",
month = "7",
day = "3",
doi = "10.1080/10428194.2018.1562180",
language = "English (US)",
volume = "60",
pages = "1972--1977",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "8",

}

TY - JOUR

T1 - Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors

T2 - results of a phase 2 study

AU - Awan, Farrukh T.

AU - Thirman, Michael J.

AU - Patel-Donnelly, Dipti

AU - Assouline, Sarit

AU - Rao, Arati V.

AU - Ye, Wei

AU - Hill, Brian

AU - Sharman, Jeff P.

PY - 2019/7/3

Y1 - 2019/7/3

N2 - Entospletinib (GS-9973), an oral, selective inhibitor of spleen tyrosine kinase (SYK), was evaluated as monotherapy in this multicenter, phase 2 study (NCT01799889) of 49 patients with relapsed or refractory chronic lymphocytic leukemia (CLL), including those with Richter’s transformation (RT), who had received prior therapy with a B-cell receptor (BCR) inhibitor. Patients were treated with entospletinib 400 mg BID as the starting dose. Sixteen patients achieved partial response and 21 had stable disease. The overall response rate was 32.7% (95% confidence interval [CI]: 21.7–45.3%). The median progression-free survival (PFS) was 5.6 (95% CI: 3.7–8.3) months. Twenty-one (of 43) patients (48.8%) experienced nodal response. Adverse events (AEs) occurred in all patients; most commonly fatigue, diarrhea, and anemia. Entospletinib monotherapy has clinical activity for patients with CLL and RT who have relapsed following therapy with BCR inhibitors.

AB - Entospletinib (GS-9973), an oral, selective inhibitor of spleen tyrosine kinase (SYK), was evaluated as monotherapy in this multicenter, phase 2 study (NCT01799889) of 49 patients with relapsed or refractory chronic lymphocytic leukemia (CLL), including those with Richter’s transformation (RT), who had received prior therapy with a B-cell receptor (BCR) inhibitor. Patients were treated with entospletinib 400 mg BID as the starting dose. Sixteen patients achieved partial response and 21 had stable disease. The overall response rate was 32.7% (95% confidence interval [CI]: 21.7–45.3%). The median progression-free survival (PFS) was 5.6 (95% CI: 3.7–8.3) months. Twenty-one (of 43) patients (48.8%) experienced nodal response. Adverse events (AEs) occurred in all patients; most commonly fatigue, diarrhea, and anemia. Entospletinib monotherapy has clinical activity for patients with CLL and RT who have relapsed following therapy with BCR inhibitors.

KW - B-cell receptor inhibitors

KW - Richter’s transformation

KW - SYK

UR - http://www.scopus.com/inward/record.url?scp=85060025577&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060025577&partnerID=8YFLogxK

U2 - 10.1080/10428194.2018.1562180

DO - 10.1080/10428194.2018.1562180

M3 - Article

C2 - 30633573

AN - SCOPUS:85060025577

VL - 60

SP - 1972

EP - 1977

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 8

ER -